Rajeev Boregowda

Rajeev Boregowda is an Associate Director in Bioassay and Molecular Analytical group. Prior to joining Sanofi, Rajeev worked in gene therapy companies such as Solid Biosciences and Sangamo Therapeutics where he led Bioassay, Molecular Biology and Chromatography groups. He was the bioassay and analytical lead for various gene therapy programs such as Duchene Muscular Dystrophy, BAG3, Fabry, PKU and Tauopathy. Before moving into gene therapy filed, Rajeev worked at Celgene Corporation (now BMS) as the Bioassay lead for a BLA stage biologics program that received approval in US and Europe. Before Celgene, he was part of the technical task force team at BMS to bring new analytical technologies to support cell line and process groups.